Navigation Links
Prostate cancer patients treated with robotic-assisted surgery can expect low recurrence of cancer
Date:10/18/2010

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

The findings were reported in this month's issue of the European Urology journal by a team of Henry Ford Hospital researchers led by Mani Menon, M.D., an internationally recognized pioneer in the use of high-precision surgical robots.

In an editorial accompanying the article, the author wrote "it is very clear that the article by Menon et al represents a land mark contribution in the area of PCa (prostate cancer) management."

Dr. Menon, director of Henry Ford's Vattikuti Urology Institute, perfected the technique for minimally invasive laparoscopic treatment of prostate cancer.

Because they were among the first surgeons in the world to use the technique, Dr. Menon and his team had a unique opportunity to test its effectiveness on the long-term survival of a large group of prostate cancer patients.

Radical prostatectomy is a treatment in which the entire diseased prostate gland and some surrounding tissue are surgically removed in hopes of preventing the cancer from spreading to other parts of the body. It has long been considered an effective treatment for localized prostate cancer.

Early studies found that about 35 percent of men suffered a recurrence within 10 years after undergoing traditional radical prostatectomy. But Henry Ford researchers suspected those results might have become outdated as the use of prostate-specific antigen (PSA) screening gained wider acceptance, allowing prostate cancer to be detected in more men at a younger age.

No studies have looked at biochemical recurrence of prostate cancer in patients diagnosed after 2000, when Dr. Menon and his team at Henry Ford began using robot-assisted surgery. Robot-assisted radical prostatectomy has since become the most widely used form of surgical treatment of localized prostate cancer in the country.

But after carefully reviewing the literature since then, Dr. Menon's team found almost no research on medium- to long-term follow-up results.

All 1,384 of the men chosen for study were diagnosed with moderately aggressive prostate cancer and underwent robot-assisted radical prostatectomy between September 2001 and May 2005. Their average age was 60.

The patients were checked for recurrence of their cancer every three months during the first year after surgery, twice during the second year, then annually. A median of five years of follow-up was used for the study.

Dr. Menon or his colleague, James Peabody, M.D., performed all of the robot-assisted surgeries in the study. While both are highly experienced surgeons, they cautioned that the study period included their own learning curve in developing the robot-assisted technique, so results may be difficult to generalize.

Still, they say, the fact that deaths from prostate cancer occurred in only 1 of 1,000 patients per year of follow-up should provide a strong endorsement of the curative role of radical prostatectomy for patients with localized prostate cancer treated in the contemporary era.

And "with five-year actuarial biochemical recurrence-free survival outcomes of 86.6 percent, robot-assisted radical prostatectomy appears to confer effective five-year prostate cancer control."

Henry Ford's robot-assisted urology program uses the da Vinci computer-enhanced, minimally invasive surgery system introduced in 1999 by Intuitive Surgical, Inc. It enables surgeons to manipulate robotic arms for precise procedures through a series of small incisions instead of the large wounds required by traditional open surgery, and provides 3-D monitoring for the entire surgical team. The potential benefits include shorter recovery times, less trauma, and reduced hospitalization costs.

It is also the basis of a nerve-sparing procedure called the Veil of Aphrodite, developed by Dr. Menon to minimize the erectile dysfunction common in men after undergoing traditional radical prostatectomy.


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Popular prostate cancer treatment associated with bone decay
2. Surgery offers long-term survival for early stage prostate cancer patients
3. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
4. Surgery found effective for patients with aggressive prostate cancer
5. Cholesterol drug may have role in treating prostate cancer
6. Prostate cancer community calls for better early detection and treatment
7. Urgent need for prostate cancer screening amongst Dutch men
8. Blood test accurately predicts death from prostate cancer up to 25 years in advance
9. Prostate Cancer Screening No Benefit to Older Men With Low PSA Levels
10. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
11. Cost of prostate cancer care varies with initial treatment choice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: